Over the years, Africa occupied the final link in the global vaccine supply chain. The continent depended overwhelmingly on vaccines produced elsewhere and was often forced to wait while wealthier nations secured access during health emergencies.
This vulnerability was exposed during successive Ebola outbreaks and became impossible to ignore during the COVID-19 pandemic. As wealthy countries accumulated vaccine supplies far beyond their immediate needs, many African nations waited months for access to lifesaving doses. The experience delivered a powerful lesson: health security cannot depend entirely on external suppliers.
READ ALSO: South Africa Tourism Outperforms Pre-Pandemic Levels
Africa is currently pursuing one of the most ambitious public health transformations in its modern history. The continent has set a goal of producing 60 percent of its vaccine requirements locally by 2040, compared with approximately 1 percent before the COVID-19 era. More than an industrial target, this ambition represents a strategic push toward health sovereignty, scientific self-reliance, economic development, and long-term pandemic preparedness.
As new disease threats continue to emerge, including recurring Ebola outbreaks and concerns about future zoonotic diseases, building a strong vaccine manufacturing ecosystem has become central to Africa’s resilience agenda.
Home to more than 1.4 billion people and approximately 17 percent of the world’s population, Africa has historically imported the vast majority of its vaccines, pharmaceuticals, and essential medical supplies. While global supply chains helped meet routine healthcare needs, they proved far less reliable during periods of crisis.
The COVID-19 pandemic highlighted the risks of this dependence. African countries faced delayed access to vaccines, supply disruptions, limited bargaining power, and heavy reliance on donor-supported procurement mechanisms. While advanced economies launched mass vaccination campaigns, many African nations struggled to secure adequate supplies.
The crisis transformed vaccine manufacturing from a healthcare issue into a strategic priority. Policymakers increasingly recognised that future pandemic resilience would require local production capacity rather than continued dependence on external markets.
The roots of Africa’s vaccine revolution can be traced to two defining health emergencies. The first was the 2014 to 2016 Ebola outbreak in West Africa, which exposed the region’s limited ability to produce vaccines and therapeutics despite global scientific advances. The second was COVID-19, which magnified those shortcomings as export restrictions and production bottlenecks left African countries vulnerable to prolonged shortages.
Together, these experiences shifted the continent’s objective from merely receiving vaccines to producing them.
At the heart of this transformation is the development of regional manufacturing hubs. South Africa, Rwanda, and Senegal have emerged as key pillars of Africa’s vaccine strategy.
South Africa has taken a leading role through Afrigen Biologics and Vaccines, demonstrating that African scientists can develop advanced mRNA vaccine technologies. Beyond COVID-19, these capabilities could support the development of vaccines for neglected tropical diseases and future viral threats.
Rwanda has rapidly positioned itself as an emerging biotechnology hub through partnerships with international pharmaceutical companies. Investments in modern facilities, technology transfer agreements, and workforce development are helping diversify Africa’s manufacturing capacity.
Meanwhile, Senegal is expanding its production capabilities to serve West African markets. Its growth reflects an important reality: no single country can supply the entire continent. Multiple regional manufacturing centres are essential to ensuring resilience, redundancy, and equitable access.
However, manufacturing facilities alone cannot guarantee vaccine security. Africa’s strategy increasingly focuses on building an entire ecosystem that includes research institutions, clinical trial networks, regulatory agencies, supply chains, skilled workforces, financing mechanisms, and procurement systems.
This systems-based approach distinguishes the current effort from earlier attempts at pharmaceutical production. One of the most important initiatives is the African Vaccine Manufacturing Accelerator, which aims to mobilise up to one billion dollars to reduce investment risks, attract private-sector participation, and support long-term market stability.
The African Continental Free Trade Area also plays a critical role by expanding market access, reducing trade barriers, and facilitating the movement of medical products across borders. These developments reflect a growing recognition that health security and economic security are deeply interconnected.
Beyond manufacturing, Africa is investing heavily in research and development capabilities. Partnerships involving the Africa Centres for Disease Control and Prevention, the World Health Organisation, and the African Research Universities Alliance are strengthening expertise in genomics, vaccine design, clinical trials, disease surveillance, and biotechnology innovation.
This investment is particularly important because future outbreaks may emerge within Africa before spreading globally. Strong local scientific capacity allows for faster detection, research, and response.
Researchers are also adapting vaccine technologies to African realities. Innovations such as thermostable vaccines, simplified distribution systems, reduced cold-chain requirements, and improved storage technologies could significantly improve access across diverse and often challenging environments.
Pandemic preparedness begins long before vaccines are manufactured. Early detection through genomic surveillance remains one of the most effective tools for containing emerging diseases.
African scientists played an important role in identifying and tracking variants during the COVID-19 pandemic. Building on that experience, countries are increasingly integrating genomic surveillance into routine public health systems rather than relying on emergency deployments during crises.
The urgency of this work has been reinforced by repeated warnings from global health experts that another pandemic is inevitable. For Africa, where outbreaks of Ebola, cholera, mpox, yellow fever, and other infectious diseases continue to occur, preparedness is no longer optional.
Health sovereignty today extends beyond manufacturing capacity. It also includes control over scientific data, genomic information, disease surveillance systems, and research institutions. These assets are increasingly viewed as strategic resources that must contribute directly to African scientific advancement.
Sustaining this momentum will require retaining Africa’s scientific talent. Competitive compensation, research funding, modern laboratories, and supportive working environments are essential if highly skilled researchers are to remain on the continent and contribute to its long-term development.
Equally important is sustainable financing. National health budgets, public-private partnerships, regional financing mechanisms, and initiatives such as the African Epidemic Fund will be critical to reducing dependence on emergency donor support and ensuring long-term resilience.
Pandemic preparedness is as much a governance challenge as it is a scientific one. Success will depend on sustained political commitment, regulatory reforms, strategic investment, regional cooperation, and public accountability over decades rather than electoral cycles.
If Africa succeeds, the continent will be able to detect outbreaks earlier, develop vaccines faster, manufacture doses locally, and respond more independently to future health emergencies. Such a transformation would mark a historic shift from dependence to self-reliance and position Africa as a stronger contributor to global health security in the decades ahead.
